Skip to main content

We've updated our website navigation
Public engagement opportunities, vacancies and our new Become a Provider section can now be found under Working With Us.
Looking for something else? Select More from the main navigation menu to access additional sections and resources.

Cancer and Blood

 Services for Children with Cancer, Service Specification (SS86), December 2024.pdf (PDF, 509Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other rare hereditary anaemias all ages, Service Specification (CP179), December 2020.pdf (PDF, 453Kb)
 Soft tissue sarcoma, Service Specification (SS149), November 2025 (PDF, 556Kb)
 Specialised Immunology, Service Specification (SS78), October 2024.pdf (PDF, 615Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278), Policy Position Statement, August 2023.pdf (PDF, 613Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280), Policy Position Statement, August 2023.pdf (PDF, 427Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024.pdf (PDF, 551Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76), June 2023.pdf (PDF, 327Kb)
 Stereotactic Ablative Body Radiotherapy (SABR), Service Specification (SS219), December 2024.pdf (PDF, 505Kb)
 Stereotactic Ablative Radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (adults), Commissioning Policy, (CP124), December 2024.pdf (PDF, 550Kb)
 Stereotactic Ablative Radiotherapy (SABR) for people aged 18 years old and above with primary kidney cancer, Commissioning Policy (CP279), June 2024.pdf (PDF, 512Kb)
 Use of plerixafor for stem cell mobilisation for CTYA with lymphoma and paediatric type solid tumours, Policy Position Statement (PP154), July 2024.pdf (PDF, 208Kb)
 Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215), October 2023.pdf (PDF, 353Kb)